| Code | CSB-RA004847MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to RO-7502175, targeting C-C chemokine receptor type 8 (CCR8), a G protein-coupled receptor preferentially expressed on regulatory T cells (Tregs) within the tumor microenvironment. CCR8 plays a critical role in the trafficking and retention of immunosuppressive Tregs to tumors, where its ligands CCL1 and CCL18 facilitate Treg recruitment and contribute to immune evasion. Elevated CCR8 expression on intratumoral Tregs has been associated with poor prognosis in various solid tumors, including colorectal, breast, and non-small cell lung cancers, making it an attractive target for cancer immunotherapy research.
RO-7502175 represents a therapeutic antibody designed to selectively deplete CCR8-positive Tregs in the tumor microenvironment while sparing peripheral Tregs, potentially enhancing anti-tumor immunity. This biosimilar antibody serves as a valuable research tool for investigating CCR8 biology, Treg function, tumor immunology, and mechanisms of immune suppression. It enables researchers to explore CCR8-targeted therapeutic strategies and evaluate combination approaches with other immunomodulatory agents in preclinical cancer models.
There are currently no reviews for this product.